Strategies to Minimize Risks and Exploitation in Phase One Trials on Healthy Subjects*

American Journal of Bioethics - United Kingdom
doi 10.1080/15265160600686281
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Safety, Pharmacokinetics, and Pharmacodynamics of the Autotaxin Inhibitor GLPG1690 in Healthy Subjects: Phase 1 Randomized Trials

Journal of Clinical Pharmacology
Pharmacology
2019English

A Brief Discussion on Strategies to Control Safety Risks of Investment and Exploitation of Overseas Mineral Resources

2015English

Grain Aflatoxins and Ways to Minimize Risks of Their Accumulation

Bulletin of the South Ural State University Series Food and Biotechnology
2019English

Escalation Strategies for Combination Therapy Phase I Trials

Pharmaceutical Statistics
StatisticsProbabilityPharmacology
2012English

Effect of Diet on Serum Creatinine in Healthy Subjects During a Phase I Study

Journal of Clinical Medicine Research
2016English

Communication About the Risks and Benefits of Phase I Pediatric Oncology Trials

Contemporary Clinical Trials
MedicinePharmacology
2015English

Communication for Doctors: How to Improve Patient Care and Minimize Legal Risks

Health Expectations
EnvironmentalPublic HealthOccupational Health
2005English

Cardiovascular Risks, Bleeding Risks, and Clinical Events From 3 Phase III Trials of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis

Advances in Therapy
MedicinePharmacology
2019English

Strategies to Improve Retention in Randomised Trials

Cochrane Database of Systematic Reviews
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy